| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Helena Moratin, Anna Thöle, Josephine Lang, Totta Ehret Kasemo, Manuel Stöth, Rudolf Hagen, Agmal Scherzad, Stephan Hackenber. Ag- but Not ZnO-Nanoparticles Disturb the Airway Epithelial Barrier at Subtoxic Concentrations. Pharmaceutics. vol 15. issue 10. 2023-10-30. PMID:37896266. |
in the nasal respiratory epithelium, cells of the mucosa represent one of the first contact points of the human organism with airborne nps. |
2023-10-30 |
2023-11-08 |
human |
| Hiroatsu Hatsukawa, Masaaki Ishikawa, Tomoyuki Hirai, Kazuo Endo, Emiko Saito, Hirotaka Matsumoto, Kouya Okazak. Comorbidity of eosinophilic chronic rhinosinusitis in chronic eosinophilic pneumonia. Respirology case reports. vol 11. issue 11. 2023-10-20. PMID:37854459. |
nasal polyps (nps) were observed in 50% of patients on endoscopy. |
2023-10-20 |
2023-11-08 |
Not clear |
| Mohamed M Badran, Abdulrahman E Alanazi, Mohamed Abbas Ibrahim, Doaa Hasan Alshora, Ehab Taha, Abdullah H Alomran. Optimization of Bromocriptine-Mesylate-Loaded Polycaprolactone Nanoparticles Coated with Chitosan for Nose-to-Brain Delivery: In Vitro and In Vivo Studies. Polymers. vol 15. issue 19. 2023-10-14. PMID:37835942. |
this study aimed to formulate chitosan (cs)-coated poly ε-caprolactone nanoparticles (pcl nps) loaded with bm for direct targeting to the brain via the nasal route. |
2023-10-14 |
2023-10-15 |
Not clear |
| Mohamed M Badran, Abdulrahman E Alanazi, Mohamed Abbas Ibrahim, Doaa Hasan Alshora, Ehab Taha, Abdullah H Alomran. Optimization of Bromocriptine-Mesylate-Loaded Polycaprolactone Nanoparticles Coated with Chitosan for Nose-to-Brain Delivery: In Vitro and In Vivo Studies. Polymers. vol 15. issue 19. 2023-10-14. PMID:37835942. |
the bm-cs-pcl nps displayed a biphasic release pattern, with an initial rapid drug release lasting for 2 h, followed by a sustained release for up to 48 h. the 0.25% cs-coated bm-cs-pcl nps showed a high level of permeation across the goat nasal mucosa, with reasonable mucoadhesive strength. |
2023-10-14 |
2023-10-15 |
Not clear |
| Mohamed M Badran, Abdulrahman E Alanazi, Mohamed Abbas Ibrahim, Doaa Hasan Alshora, Ehab Taha, Abdullah H Alomran. Optimization of Bromocriptine-Mesylate-Loaded Polycaprolactone Nanoparticles Coated with Chitosan for Nose-to-Brain Delivery: In Vitro and In Vivo Studies. Polymers. vol 15. issue 19. 2023-10-14. PMID:37835942. |
these findings suggested that the optimized 0.25% cs-coated bm-cs-pcl nps hold promise for successful nasal delivery, thereby improving the therapeutic efficacy of bm. |
2023-10-14 |
2023-10-15 |
Not clear |
| Giovanna Lucia Piazzetta, Nadia Lobello, Emanuela Chiarella, Alberta Rizzuti, Corrado Pelaia, Girolamo Pelaia, Nicola Lombard. Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab. Journal of personalized medicine. vol 13. issue 9. 2023-09-28. PMID:37763171. |
the inclusion criteria were: age ≥ 18 years; confirmed diagnosis of chronic rhinosinusitis with severe nasal polyposis; disease severity with nps nasal polyposis endoscopic score total score ≥ 5 and/or snot-22 ≥ 50; previous treatment failure due to lack of efficacy or discontinuation of systemic corticosteroid therapy and/or non-response or recurrence following surgery. |
2023-09-28 |
2023-10-07 |
Not clear |
| Tanya M Laidlaw, Andrew Menzies-Gow, Scott Caveney, Joseph K Han, Nicole Martin, Elliot Israel, Jason K Lee, Jean-Pierre Llanos, Neil Martin, Ayman Megally, Bhavini Parikh, Sylvia Vong, Tobias Welte, Jonathan Corre. Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR. Journal of asthma and allergy. vol 16. 2023-09-11. PMID:37692126. |
we assessed the efficacy of tezepelumab in patients with severe asthma with or without nasal polyps (nps) in the 2 years before randomization in navigator. |
2023-09-11 |
2023-10-07 |
human |
| Hanna K Mandl, Jessa E Miller, Daniel M Beswic. Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps. Otolaryngologic clinics of North America. 2023-09-08. PMID:37684154. |
a substantial portion of asthma and nasal polyps (nps) share a common pathogenesis, which includes type 2-mediated inflammation. |
2023-09-08 |
2023-10-07 |
Not clear |
| Lihong Chang, Haotian Wu, Weiqiang Huang, Yue Li, Ye Chen, Xia Li, Zhouzhou Yao, Xiaohong Chen, Xiaoping Lai, Rui Zheng, Zizhen Huang, Xifu Wu, Gehua Zhan. IL-21 induces pyroptosis of Treg cells via Akt-mTOR-NLRP3-caspase 1 axis in eosinophilic chronic rhinosinusitis. The Journal of allergy and clinical immunology. vol 152. issue 3. 2023-09-07. PMID:37164271. |
regulatory t (treg) cells, which prevent inflammation-induced eosinophil infiltration, are deficient in nasal polyps (nps) in patients with eosinophilic chronic rhinosinusitis (ecrs). |
2023-09-07 |
2023-10-07 |
Not clear |
| Marn Joon Park, Youjeong Seo, Soo Hyun Jo. Seromucinous Hamartoma of the Sinonasal Cavity. Ear, nose, & throat journal. 2023-08-26. PMID:37632332. |
the 3 most prevalent unilateral benign mass lesions in such individuals are nasal polyps (nps) and inverted papillomas (ips). |
2023-08-26 |
2023-09-07 |
Not clear |
| Kathrin Gerstacker, Manuel Christoph Ketterer, Till Fabian Jakob, Tanja Hildenbran. Real Life Observational Study of Treatment Success of Monoclonal Antibodies for Refractory Chronic Rhinosinusitis with Nasal Polyps. Journal of clinical medicine. vol 12. issue 13. 2023-07-14. PMID:37445408. |
changes in snot-22 and nasal polyp score (nps), as well as subjective change in sense of smell, number of sinus surgeries prior to and during treatment, comorbidities, discontinuation or change of monoclonal antibody and adverse events were evaluated. |
2023-07-14 |
2023-08-14 |
Not clear |
| Mara Gutiérrez-Sánchez, María Maricela Carrasco-Yépez, José Correa-Basurto, Gema Lizbeth Ramírez-Salinas, Saúl Rojas-Hernánde. Two MP2CL5 Antigen Vaccines from Naegleria fowleri Stimulate the Immune Response against Meningitis in the BALB/c Model. Infection and immunity. 2023-06-05. PMID:37272791. |
the survival rate and immune response of immunized mice with both antigens and challenged with n. fowleri trophozoites were measured in the nose-associated lymphoid tissue (nalt) and nasal passages (nps) by flow cytometry and enzyme-linked immunosorbent assay (elisa). |
2023-06-05 |
2023-08-14 |
mouse |
| Emanuela Sitzia, Sara Santarsiero, Giulia Marini, Fabio Majo, Marcello De Vincentiis, Giovanni Cristalli, Maria Cristina Artesani, Alessandro Giovanni Fiocch. Endotypes of Nasal Polyps in Children: A Multidisciplinary Approach. Journal of personalized medicine. vol 13. issue 5. 2023-05-27. PMID:37240876. |
nasal polyps (nps) are rarely reported in childhood and usually represent red flags for systemic diseases, such as cystic fibrosis (cf), primary ciliary dyskinesia (pcd) and immunodeficiencies. |
2023-05-27 |
2023-08-14 |
Not clear |
| Jessica Braid, Lutaf Islam, Cristian Gugiu, Theodore A Omachi, Helen Dol. Meaningful changes for efficacy outcomes in patients with chronic rhinosinusitis with nasal polyps. The World Allergy Organization journal. vol 16. issue 5. 2023-05-23. PMID:37214171. |
nasal polyp score (nps) and nasal congestion score (ncs) are commonly used clinical trial endpoints to determine improvements in response to treatment in patients with chronic rhinosinusitis with nasal polyps (crswnp). |
2023-05-23 |
2023-08-14 |
Not clear |
| Axel Nordström, Mattias Jangard, Marie Svedberg, Michael Ryott, Maria Kumli. Distinct eicosanoid patterns in severe recalcitrant nasal polyposis. International forum of allergy & rhinology. 2023-05-14. PMID:37179460. |
although altered eicosanoid levels are related to disease severity in chronic rhinosinusitis with nasal polyps (crswnp), identifying patients prone to recurrent nps is still difficult. |
2023-05-14 |
2023-08-14 |
Not clear |
| Cosimo Galletti, Maria Antonietta Barbieri, Francesco Ciodaro, Francesco Freni, Francesco Galletti, Edoardo Spina, Bruno Gallett. Effectiveness and Safety Profile of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Real-Life Data in Tertiary Care. Pharmaceuticals (Basel, Switzerland). vol 16. issue 4. 2023-04-28. PMID:37111387. |
a statistically significant reduction in the sino-nasal outcome test 22 (snot-22) and nasal polyps score (nps) was shown at the 6th and 12th months compared to baseline values (snot-22, -37 and -50, |
2023-04-28 |
2023-08-14 |
Not clear |
| Rebecca Maher, Almudena Moreno-Borrallo, Dhruvi Jindal, Binh T Mai, Eduardo Ruiz-Hernandez, Andrew Harki. Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery. Pharmaceutics. vol 15. issue 3. 2023-03-29. PMID:36986607. |
nps can be specifically designed for intranasal administration by tailoring their size and coating with mucoadhesive agents or other moieties that promote transport across the nasal mucosa. |
2023-03-29 |
2023-08-14 |
Not clear |
| Dilyana Georgieva, Denitsa Nikolova, Elena Vassileva, Bistra Kostov. Chitosan-Based Nanoparticles for Targeted Nasal Galantamine Delivery as a Promising Tool in Alzheimer's Disease Therapy. Pharmaceutics. vol 15. issue 3. 2023-03-29. PMID:36986689. |
in this work, chitosan-based nanoparticles (nps) were studied as potential gh delivery vehicles for nasal application. |
2023-03-29 |
2023-08-14 |
Not clear |
| Bo You, Ting Zhang, Wei Zhang, Yinyin Pei, Danyi Huang, Yun Lei, Shaocong Zhang, Changyu Qiu, Jie Zhang, Zhifeng Gu, Lei Cheng, Jing Che. IGFBP2 derived from PO-MSCs promote epithelial barrier destruction by activating FAK signaling in nasal polyps. iScience. vol 26. issue 3. 2023-03-03. PMID:36866245. |
the nasal polyps (nps) microenvironment comprises multiple cell types, including mesenchymal stromal cells (mscs). |
2023-03-03 |
2023-08-14 |
mouse |
| María Sandra Domínguez-Sosa, María Soledad Cabrera-Ramírez, Miriam Del Carmen Marrero-Ramos, Delia Dávila-Quintana, Carlos Cabrera-López, Teresa Carrillo-Díaz, Jesús Javier Benítez Del Rosari. Real-Life Effectiveness of Mepolizumab in Refractory Chronic Rhinosinusitis with Nasal Polyps. Biomedicines. vol 11. issue 2. 2023-02-25. PMID:36831021. |
nasal endoscopic polyp score (nps), visual analogue scale (vas) symptom score, sinonasal outcome test (snot-22), asthma control test (act) score, fractional exhaled nitric oxide (feno), eosinophils blood cells and prednisone intake were assessed at baseline and after 6 months. |
2023-02-25 |
2023-08-14 |
Not clear |